Perovial®
Medical device
Perovial® is the first HA-based option for the management of Peyronie’s disease in its acute phase1.
Highlights
High level of novelty
Classified as a high level of novelty device1
Improvement
Improvement in penile curvature, plaque size, and erectile function13,6,7
Improves outcome
Improves outcome in terms of penile pain reduction and patients’ satisfaction6,7
Good safety and tolerability
Good safety profile and tolerability in clinical studies3,6,7
Protocol
Weekly for 10-12 weeks according to the doctor’s judgment2
Clinical evidence
Regression in plaque size7,8
Perovial® leads to a measurable decrease in penile curvature3,6,7,8
Perovial® improves erectile function6,7
Perovial® showed significant improvement in penile pain compared to verapamil and baseline and patient satisfaction6,7,8
Perovial® showed a good safety profile and good tolerability3,5,7
Section reserved for healthcare professionals
This section contains information intended for healthcare professionals. By continuing, you confirm that you are a healthcare professional authorized to access this content.
Are you a healthcare professional (HCP)?
References
- 1 / European Commission. Expert decision and opinion in the context of the Clinical Evaluation Consultation Procedure (CECP).
- 2 / PEROVIAL®. Instructions for Use.
- 3 / Favilla V, et al. Andrology. 2017;5(4):771-5.
- 4 / Garantziotis S, Savani RC. Matrix Biol. 2019;78-79:1-10.
- 5 / Iaconisi GN, et al. Int J Mol Sci. 2023;24(12):10296.
- 6 / Cocci A, et al. World J Mens Health. 2021;39(2):352-7.
- 7 / Zucchi A, et al. Sex Med. 2016;4(2):e83-8.
- 8 / Cai T, et al. World J Mens Health. 2021;39(3):526-32.